Herbal/hormonal dietary supplement possibly associated with prostate cancer progression

Shahrokh F. Shariat, Dolores J. Lamb, Radha G. Iyengar, Claus Roehrborn, Kevin M. Slawin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Patients seek herbal/hormonal dietary supplements (HHDS) to prevent and/or solve health and aging issues. After two men developed an unusual course of clinically aggressive prostate cancer within months of starting daily consumption of the same HHDS product, we investigated the effect of this product on prostate cancer progression. Methods: We evaluated serum levels of total testosterone, luteinizing hormone, and follicle-stimulating hormone and screened prostate biopsy and metastatic specimens for androgen receptor protein expression and mutations. We did hormone analyses and capillary electrophoresis. We tested the effect of the HHDS product on androgen receptor-negative (DU-145 and PC-3) and androgen receptor-positive (LNCaP) human prostate cancer cell lines. Results: Both patients had low hormone levels. The androgen receptor was expressed in all primary and metastatic prostate cancer tissues and no mutations were identified. Hormone analysis revealed that the HHDS contained testosterone and estradiol. The HHDS product was a more potent dose-dependent stimulator of cancer cell growth than testosterone both in androgen receptor-negative and receptor-positive cell lines. Blocking experiments with increasing concentrations of bicalutamide did not prevent the HHDS product - stimulated growth. We filed an adverse event report with the Food and Drug Administration who issued a warning letter. The manufacturer responded by removing this HHDS product from the market. Conclusions: The HHDS product contained one or more endocrinologically active tumor-promoting components that had cellular androgen receptor status - independent activity. The HHDS product exhibited potent prostate cancer growth stimulatory activity that was more powerful than that of testosterone, independent of the androgen-receptor status of prostate cancer cells, and resistant to antiandrogen blockade.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalClinical Cancer Research
Volume14
Issue number2
DOIs
StatePublished - Jan 15 2008

Fingerprint

Dietary Supplements
Androgen Receptors
Prostatic Neoplasms
Testosterone
Hormones
Growth
Androgen Antagonists
Cell Line
Mutation
Capillary Electrophoresis
Follicle Stimulating Hormone
United States Food and Drug Administration
Luteinizing Hormone
Prostate
Estradiol
Neoplasms
Biopsy
Health
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. / Shariat, Shahrokh F.; Lamb, Dolores J.; Iyengar, Radha G.; Roehrborn, Claus; Slawin, Kevin M.

In: Clinical Cancer Research, Vol. 14, No. 2, 15.01.2008, p. 607-611.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Lamb, Dolores J. ; Iyengar, Radha G. ; Roehrborn, Claus ; Slawin, Kevin M. / Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 2. pp. 607-611.
@article{bb4116f2040e4743b5fc6083d8526dd1,
title = "Herbal/hormonal dietary supplement possibly associated with prostate cancer progression",
abstract = "Background: Patients seek herbal/hormonal dietary supplements (HHDS) to prevent and/or solve health and aging issues. After two men developed an unusual course of clinically aggressive prostate cancer within months of starting daily consumption of the same HHDS product, we investigated the effect of this product on prostate cancer progression. Methods: We evaluated serum levels of total testosterone, luteinizing hormone, and follicle-stimulating hormone and screened prostate biopsy and metastatic specimens for androgen receptor protein expression and mutations. We did hormone analyses and capillary electrophoresis. We tested the effect of the HHDS product on androgen receptor-negative (DU-145 and PC-3) and androgen receptor-positive (LNCaP) human prostate cancer cell lines. Results: Both patients had low hormone levels. The androgen receptor was expressed in all primary and metastatic prostate cancer tissues and no mutations were identified. Hormone analysis revealed that the HHDS contained testosterone and estradiol. The HHDS product was a more potent dose-dependent stimulator of cancer cell growth than testosterone both in androgen receptor-negative and receptor-positive cell lines. Blocking experiments with increasing concentrations of bicalutamide did not prevent the HHDS product - stimulated growth. We filed an adverse event report with the Food and Drug Administration who issued a warning letter. The manufacturer responded by removing this HHDS product from the market. Conclusions: The HHDS product contained one or more endocrinologically active tumor-promoting components that had cellular androgen receptor status - independent activity. The HHDS product exhibited potent prostate cancer growth stimulatory activity that was more powerful than that of testosterone, independent of the androgen-receptor status of prostate cancer cells, and resistant to antiandrogen blockade.",
author = "Shariat, {Shahrokh F.} and Lamb, {Dolores J.} and Iyengar, {Radha G.} and Claus Roehrborn and Slawin, {Kevin M.}",
year = "2008",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-07-1576",
language = "English (US)",
volume = "14",
pages = "607--611",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Herbal/hormonal dietary supplement possibly associated with prostate cancer progression

AU - Shariat, Shahrokh F.

AU - Lamb, Dolores J.

AU - Iyengar, Radha G.

AU - Roehrborn, Claus

AU - Slawin, Kevin M.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Background: Patients seek herbal/hormonal dietary supplements (HHDS) to prevent and/or solve health and aging issues. After two men developed an unusual course of clinically aggressive prostate cancer within months of starting daily consumption of the same HHDS product, we investigated the effect of this product on prostate cancer progression. Methods: We evaluated serum levels of total testosterone, luteinizing hormone, and follicle-stimulating hormone and screened prostate biopsy and metastatic specimens for androgen receptor protein expression and mutations. We did hormone analyses and capillary electrophoresis. We tested the effect of the HHDS product on androgen receptor-negative (DU-145 and PC-3) and androgen receptor-positive (LNCaP) human prostate cancer cell lines. Results: Both patients had low hormone levels. The androgen receptor was expressed in all primary and metastatic prostate cancer tissues and no mutations were identified. Hormone analysis revealed that the HHDS contained testosterone and estradiol. The HHDS product was a more potent dose-dependent stimulator of cancer cell growth than testosterone both in androgen receptor-negative and receptor-positive cell lines. Blocking experiments with increasing concentrations of bicalutamide did not prevent the HHDS product - stimulated growth. We filed an adverse event report with the Food and Drug Administration who issued a warning letter. The manufacturer responded by removing this HHDS product from the market. Conclusions: The HHDS product contained one or more endocrinologically active tumor-promoting components that had cellular androgen receptor status - independent activity. The HHDS product exhibited potent prostate cancer growth stimulatory activity that was more powerful than that of testosterone, independent of the androgen-receptor status of prostate cancer cells, and resistant to antiandrogen blockade.

AB - Background: Patients seek herbal/hormonal dietary supplements (HHDS) to prevent and/or solve health and aging issues. After two men developed an unusual course of clinically aggressive prostate cancer within months of starting daily consumption of the same HHDS product, we investigated the effect of this product on prostate cancer progression. Methods: We evaluated serum levels of total testosterone, luteinizing hormone, and follicle-stimulating hormone and screened prostate biopsy and metastatic specimens for androgen receptor protein expression and mutations. We did hormone analyses and capillary electrophoresis. We tested the effect of the HHDS product on androgen receptor-negative (DU-145 and PC-3) and androgen receptor-positive (LNCaP) human prostate cancer cell lines. Results: Both patients had low hormone levels. The androgen receptor was expressed in all primary and metastatic prostate cancer tissues and no mutations were identified. Hormone analysis revealed that the HHDS contained testosterone and estradiol. The HHDS product was a more potent dose-dependent stimulator of cancer cell growth than testosterone both in androgen receptor-negative and receptor-positive cell lines. Blocking experiments with increasing concentrations of bicalutamide did not prevent the HHDS product - stimulated growth. We filed an adverse event report with the Food and Drug Administration who issued a warning letter. The manufacturer responded by removing this HHDS product from the market. Conclusions: The HHDS product contained one or more endocrinologically active tumor-promoting components that had cellular androgen receptor status - independent activity. The HHDS product exhibited potent prostate cancer growth stimulatory activity that was more powerful than that of testosterone, independent of the androgen-receptor status of prostate cancer cells, and resistant to antiandrogen blockade.

UR - http://www.scopus.com/inward/record.url?scp=38949166047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949166047&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1576

DO - 10.1158/1078-0432.CCR-07-1576

M3 - Article

C2 - 18223237

AN - SCOPUS:38949166047

VL - 14

SP - 607

EP - 611

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -